The immune function of retrovirus-mediated gene modified (GM) T cells is critical for
Introduction
The immune function of retrovirus-mediated gene modified (GM) T cells is critical for a beneficial effect to follow their adoptive transfer into patients. The majority of retroviral vectors used in this therapeutic strategy are derived from mammalian C-type murine leukemia viruses (MLVs), and infect only dividing cells. 1 Therefore, ex vivo expansion of the target cells is required for efficient gene transfer with these vectors. [2] [3] [4] [5] [6] [7] [8] The process of ex vivo expansion may alter the function of GM T cells. In fact, there is evidence to suggest that the expansion process rather than the integration or expression of the transgene may have the largest effect on the function of GM T cells in vitro and in animal models. 2, 4, 6, [9] [10] [11] [12] [13] In humans, although the data available are still limited, a number of trials showed that GM T cells can have reduced function in vivo. [14] [15] [16] Phytohemagglutinin (PHA) is a common polyclonal stimulus used in protocols of retroviral transduction. 2, 6, 13, 14, 16 Clinical data emerging from trials that use PHA-expanded GM T-lymphocytes showed that, although some benefit can derive from their infusion, PHA-expanded GM T cells have reduced func-
PHA and CD3/CD28 on the distribution of CCR7/CD45RA T cell functional subsets, which may explain the functional differences observed. While CD3/CD28 stimulation parallels the lineage differentiation pattern induced by antigens in physiological conditions, PHA induces a skewed distribution of the CCR7/CD45RA functional T cell subsets, with near disappearance of the subpopulations that display the effector phenotype. Overall, this study demonstrates a functional disadvantage for transduction protocols based on PHA, uncovers mechanisms that may explain this functional effect, and provides us with information to design and select transduction protocols with an improved functional outcome.
Gene Therapy (2002) 9, 1359-1368. doi:10.1038/sj.gt.3301807 tion in vivo when compared with their unmanipulated counterparts. 14, 16 Despite these findings, the in vitro mechanism and functional effect of PHA-expansion on T cells remain unclear.
Human T-lymphocytes are heterogeneous in their putative markers of activation, differentiation, adhesion and migration. The nature of the cells that mediate the different facets of T cell-dependent immune function has remained largely undefined. [17] [18] [19] [20] [21] Functional characterisation of T-lymphocytes has recently been shown by Sallusto et al 22 on the basis of their expression of the chemokine receptor CCR7 and the memory marker CD45RA. CCR7 Ϫ /CD45RA Ϫ effector memory T (T EM ) cells display an immediate effector functional profile including cytolytic capacity and expression of the cytotoxic mediator perforin. Conversely, CCR7 Although the pattern of lineage differentiation of T cell functional subsets is still a matter of debate, evidence from others has confirmed the ability of CCR7 expression to discriminate populations with different functional properties. [23] [24] [25] In this study we have analyzed the effect of polyclonal expansion and subsequent transduction on the function of primary human T-lymphocytes, and then explored the underlying mechanisms. Our results show that PHA can lead to an impairment of the immune competence of these cells in vitro, as determined by allogeneic and viral antigen-specific responses. This functional effect depends primarily on the intensity and duration of the expansion process, and not on the exposure to retroviral particles or transgene expression. In addition, we show that PHAinduced functional impairment of human T cells is mediated, at least in part, through a rapid distortion of the distribution of their functional subsets, with a marked increase of T CM cells and a near disappearance of the CCR7 -subsets that display the effector phenotype. These results provide an in vitro explanation for the defective function of PHA-expanded GM T cells reported in clinical trials, and provide us with information critical to select and develop protocols of retroviral transduction that preserve the function of GM T cells and can potentially improve the clinical benefit of this application.
Results

Expansion of primary human T-lymphocytes with PHA impairs their function, as compared with CD3/CD28-stimulated and fresh unmanipulated counterparts
In order to study the effect of ex vivo expansion on the functional outcome of the transduced T-lymphocytes, peripheral blood lymphocytes (PBMCs) from healthy donors were expanded in parallel with PHA or immobilized anti-CD3 and anti-CD28 (iCD3/iCD28) in the presence of IL2. Their proliferative responses and cell cycle distribution were then analyzed. To ensure that any functional differences observed were not due to different levels of stimulation, we identified concentrations of PHA and iCD3/iCD28 that induced comparable levels of entry to cell cycle and proliferation (ie nuclear membrane breakdown to allow viral integration), 1 as shown in Figure 1 .
We then studied the allo-reactive capacity of expanded PBMCs. After prior expansion with equivalent doses of PHA or iCD3/iCD28, PBMCs from each donor were cultured in a mixed lymphocyte reaction (MLR) with irradiated allogeneic stimulators ( Figure 2 ). Our results showed that ex vivo polyclonal expansion could alter the allo-reactive capacity of T cells in vitro. This defective allo-reactivity was stimulus-dependent and particularly manifest at higher concentrations. At levels of stimulation that induced comparable proliferative responses, iCD3/iCD28 preserved the allo-reactive capacity of the expanded T cells to a greater extent than PHA ( Figure  2a ). In addition, allo-stimulated cells that had been previously expanded with iCD3/iCD28 exhibited a higher cytotoxic capacity than their PHA-expanded counterparts (Figure 2b ). In keeping with this finding, the intracellular expression of perforin, an important cytolytic mediator in T cells, was lower in PHA-pre-expanded T cells than in those pre-expanded with iCD3/iCD28 (Figure 2c) .
In addition to allo-reactivity, another important aspect of the function of ex vivo expanded and transduced Tlymphocytes is their capacity to mediate antiviral immune surveillance. 12, 15 To address this functional issue, we extended our analysis to explore the capacity of PHAexpanded T cells to mount antigen-specific responses against immunodominant peptides derived from Epstein-Barr virus (EBV) and cytomegalovirus (CMV). PBMCs per well were initially expanded with either PHA or iCD3/iCD28 as described in Figure 1 described in Materials and methods ( Figure 3 ). After stimulation, the development of virus-specific responses in vitro was monitored using HLA tetrameric complexes loaded with the relevant peptides that allow direct evaluation of antigen-specific CD8 + cytotoxic T-lyphocytes (CTLs). Both PHA and iCD3/iCD28 pre-expanded T cells gave rise to EBV and CMV-specific HLA-tetramer positive CTLs (Figure 3a ). HLA-tetramer positive CTLs derived from iCD3/iCD28-expanded cells exhibited higher levels of expression of the cytolytic mediator perforin ( Figure 3b ). Although HLA-tetramer positive cells derived from both PHA and iCD3/iCD28-expanded PBMCs produced IFN␥ upon peptide-specific stimulation, the amount of IFN␥ per cell was lower in those generated after PHA-expansion ( Figure 3c ). The expression of perforin and IFN␥ in HLA-tetramer positive cells derived from fresh unmanipulated PBMCs is similar to that of iCD3/iCD28-pre-expanded HLAtetramer positive cells. Other functional mediators such as Granzyme A were expressed at similar levels by HLAGene Therapy tetramer positive CTLs derived from lymphocytes expanded with either polyclonal stimulus (data not shown).
Figure 3 In vitro-generated EBV and CMV-specific CD8
The influence of retroviral transduction and transgene expression on the functional profile of T cells expanded with PHA or iCD3/iCD28
The results of our study show that ex vivo expansion with PHA has an impact on the function of ex vivo expanded and transduced T cells. We next investigated whether subsequent retroviral infection and expression of a transgene might have an additional effect on this functional profile. We expanded PBMCs in parallel with 0.5 g/ml PHA or 0.5 g/ml iCD3/iCD28 and then transduced them with VSV-G pseudotyped pCC1/tNGFR particles as described in Material and methods. The levels of transduction in four independent experiments were 18.75 ± 7.59% (mean ± s.d.) tNGFR+ with PHA and 27.50 ± 10.47% tNGFR+ with iCD3/iCD28. We analyzed the expression of intracellular perforin in these samples ( Figure 4 ). Retroviral transduction of the expanded PBMCs did not modify the pattern of perforin expression induced by the expansion alone, and T cells initially expanded with PHA and then transduced showed a lower percentage of perforin expression than those preexpanded with iCD3/iCD28. In addition, cells that had undergone expansion and transduction showed the same results irrespective of the successful expression of the tNGFR transgene. These findings further support the idea that it is the expansion rather than the integration or the transgene expression that determines the functional outcome of transduction protocols. 
Polyclonal expansion with PHA induces skewed distribution of CCR7/CD45RA memory and effector T cell functional subsets
Previous attempts to identify the changes that render ex vivo expanded T cells less functional have been difficult due to T cell heterogeneity. [17] [18] [19] [20] [21] Combined analysis of CD45RA and CCR7 expression has recently enabled improved characterization of T cell functional subsets. 22, 23 Our results showed marked differences between polyclonal stimulation with PHA and iCD3/iCD28 with regard to the functional outcome of the expanded T-lymphocytes, and in particular to their expression of functional markers, such as perforin. Therefore, we decided to explore whether the functional profile induced by these polyclonal stimuli could be related to changes in the distribution of the CD45RA/CCR7 subsets. As in previous experiments, PBMCs were expanded in parallel with increasing doses of either PHA or iCD3/iCD28. Changes in the distribution of their CCR7/CD45RA subsets were analyzed daily within both CD8
+ and CD4 + T cells. PHAinduced expansion of human primary T-lymphocytes led to a distortion of the distribution of these subsets. PHA induced a marked increase of the CD8
+ T CM population and near disappearance of the CD8 + T N cells, and more importantly, of the CD8 + CCR7 -T EM and T Ef subsets, which display the effector phenotype, including cytotoxic capacity and perforin expression ( Figure 5 ). This skewed distribution was dose-dependent and occurred rapidly, manifesting within 48 h of stimulation at the highest dose, and by days 4 or 5 at lower doses, and was maintained for up to 10 days of expansion ( Figure 6 ). Conversely, doses of iCD3/iCD28 that led to similar levels of proliferation had a very different effect on the distribution of these subsets in expanded PBMCs from the same donors. iCD3/iCD28 stimulation maintained a predominant population of cells with a CD8
+ CCR7 -/CD45RA -T EM phenotype even at higher doses or longer periods of expansion ( Figures 5 and 6 ). This latter profile is more physiological, as it mirrors the subset distribution induced by antigen-specific stimulation (own data not shown, manuscript in preparation). 23, 26 Although functional characterization of T cells based on CCR7 and CD45RA expression has predominantly been studied within CD8
+ T cells it is equally valid for CD4 + T cells. 22 In fact, these phenotypic transformations, induced by PHA and iCD3/iCD28, were not limited to the CD8 + T cell subsets presented in Figures 5 and 6 . CD4 + T cells underwent phenotypic changes similar to their CD8 + counterparts (data not shown).
Upon antigen-specific stimulation, CD8 + CCR7/ CD45RA-defined T cell subsets have been shown to follow a lineage differentiation pattern from naive CD8
+ T N cells into T CM , then T EM and finally T Ef . 22, 23 The final phenotype of these subsets after differentiation is the result of three main processes: proliferation, survival and shift in the CCR7/CD45RA-phenotype of the cells. To study the effect of polyclonal stimulation on the lineage differentiation pattern of T cells, we isolated the four different CD8 + T cell subsets by cell sorting, expanded these purified populations in parallel with either stimuli as before, and analyzed the proliferation, apoptosis and CCR7/CD45RA-phenotype in the cultures (Figure 7 ). CD8 + T N cells exhibited high proliferative capacity, high survival and a shift towards a CCR7
-phenotype in response to both PHA and iCD3/iCD28, albeit this was quicker with PHA. CD8 + T Ef cell responses to PHA and iCD3/iCD28 were also comparable, showing very low proliferation and no evidence of phenotypic changes before they disappeared as a result of their high level of apoptosis. In response to either iCD3/iCD28 or PHA, CD8
+ T CM cells demonstrated high proliferative capacity and low levels of apoptosis. In addition, iCD3/iCD28-mediated expansion of CD8
+ T CM cells led to down-regulation of CCR7 (greater than 50% by day 4 and 75% by day 8) and shift of the majority of the sorted population into a CCR7 -/CD45RA -effector phenotype. This response to iCD3/iCD28 polyclonal stimulation mimics their response to antigen-specific stimulation. Conversely, PHA-stimulation of this same subset prevented CD8
+ T CM cells from progressing to the next stage of differentiation, thus leading to maintained expression of CCR7 in the culture. CD8 + T EM cells had a more complex response to polyclonal stimulation. Their proliferative response was somewhat delayed compared with the CCR7 + subsets, as confirmed by the analysis of 3 H-thymidine incorporation to the cultures at 72 h. In addition, reduced survival was observed, with higher percentages of apoptosis detected early in the cultures, which then decreased progressively in the following days. In response to either PHA or iCD3/iCD28, a small percentage of CD8 + T EM cells after antigen-specific stimulation has been preGene Therapy viously described. 23 In keeping with this,~20% of iCD3/iCD28-expanded CD8 + T EM cells up-regulated CCR7. However, in response to PHA, many more (~75%) of the T EM expanded counterparts up-regulated CCR7, contributing to the skewed phenotype described above.
Discussion
Evidence from HSVtk transgenic murine models, 10, 11 and from protocols of transduction based on antigen-specific or allogeneic stimulation, 3, 27, 28 suggests that ex vivo expansion with polyclonal stimuli is a major contributing factor to the functional outcome of transduction protocols. Nevertheless, polyclonal expansion continues to be a prerequisite for the majority of protocols of retroviral transduction of primary T cells. Therefore, it is important to identify and select protocols of polyclonal expansion that potentially preserve the function of GM T cells. Functional analysis of protocols of polyclonal stimulation has been very limited so far, and focused on the function of CD3-stimulated GM T cells in vitro compared with CD3/CD28. 4, 12 Despite PHA being a common polyclonal stimulus for transduction 2, 6, 13, 14, 16 and recent clinical data showing that the function of PHA-expanded GM T cells is poor in vivo compared with their unmanipulated counterparts, 16 no such comparative functional analysis has been published for PHA. In this study, we have explored the functional effect of PHA on T cells in vitro, compared it with iCD3/iCD28 stimulation, and then investigated the mechanisms leading to this functional effect.
Our results confirm that expansion of primary human T-lymphocytes with PHA can lead to functional impair- ment in vitro. At doses of PHA and iCD3/iCD28 that lead to comparable levels of entry to cell cycle and proliferation, PHA compares poorly to iCD3/iCD28 in terms of the function of the expanded cells in vitro. This defective functional profile in vitro consisted of reduced proliferative and cytotoxic responses to allogeneic stimulators and low expression of perforin. This functional impairment was evident not only in response to allogeneic stimulation, but also to virus-specific antigens from CMV and EBV. This may have important clinical implications in the post-bone marrow transplantation setting, where effective antiviral immune surveillance is necessary to prevent EBV-associated lymphoproliferative disease and CMV reactivation. Our findings concur with those of recent studies showing that T cells costimulated with anti-CD3/anti-CD28 can retain normal function. 15, 29 They also suggest that even for iCD3/iCD28 costimulation, the intensity and duration of expansion need to be optimized to preserve the function.
The observation that the stimulus has an effect on the function of T cells does not rule out the possibility that other phases of the transduction process might induce additional functional defects. Our transduction results show that the differential expression of perforin between PHA and iCD3/iCD28-expanded cells is not altered by the transduction process. Similarly, there was no change to the differential perforin expression, either in cells that successfully express the transgene or in those that do not. These results suggest that the functional impact resulting from the manipulation associated with PHA-based retroviral transduction is due to the expansion per se rather than to retroviral infection or expression of the transgene. We cannot exclude the possibility that these might affect alternative functional parameters that we have not analyzed.
This work aimed to analyze function rather than the efficiency of transduction. Even so, our transduction results show that adequate levels of transduction can be achieved following expansion protocols that comparatively preserve the function of the target cells. In our hands, 0.5 g/ml PHA or 0.5 g/ml iCD3 plus 1 g/ml iCD28 led to levels of transduction comparable to what many other published protocols achieve. 3, 7, 14, 15, 27, 30, 31 Most likely, the incorporation in the protocol of elements such as retronectin, three rounds of infection, and a retroviral envelope with enhanced host range and the capacity to be concentrated, were critical to the results obtained. However, further analysis of these aspects is not possible from the design and results of this study. Lastly, it is interesting that even at doses of stimuli that led to similar proliferative responses, iCD3/iCD28-expanded cells were transduced to somewhat higher percentages than their PHA counterparts. Preferential transduction on retronectin of iCD3/iCD28-stimulated T cells has been previously associated with an increased co-localization of viruses and target cells on retronectin molecules mediated through the effect of CD3/CD28 cross-linking on VLA4 and VLA5 integrins. 32 In addition, costimulation of transduced T cells via CD3 and CD28 leads to increased transcription of the integrated retrovirus. 33 These results provide further support for the advantage of iCD3/iCD28-stimulation over PHA.
The mechanism by which polyclonal stimuli might alter the immune competence of T cells remains largely unresolved. Changes in the CD4/CD8 T cell ratio, the expression of activation markers such as CD25 or CD69, and the TcR-␤V repertoire after transduction have shed little light on this functional difference. 3, 4, 27, 34, 35 Combined analysis of CD45RA and CCR7 expression shows marked differences in the distribution of functional subsets after expansion with PHA or iCD3/iCD28. Our results with unfractionated and sorted populations demonstrate that PHA expansion alters, in a dose-and time-dependent fashion, the distribution of CCR7/CD45RA functional T cell subsets, with near disappearance of the CCR7 -populations that display an effector phenotype. Conversely, iCD3/iCD28 stimulation reproduces the differentiation steps and functional phenotype induced by antigen-specific stimulation. 23, 26 To the best of our knowledge, this is the first report of a non-specific mitogen, such as PHA, having an effect on the differentiation of functional T cell subpopulations.
In vivo, there is clear evidence that T cells with high level of perforin expression and effector phenotype are necessary for adequate control of infection. 23, 36 In the hemopoietic stem cell transplant setting, a perforindependent pathway is required for T cell-mediated graftversus-leukemia effect 37 and for T cell-dependent control of EBV-associated post-transplant lymphoproliferative disease. 38 These in vivo findings would further suggest that the functional phenotype that we have just described for iCD3/iCD28-expanded T cells may be advantageous, compared with that of PHA, for adoptive transfer into patients. However, the effect in vivo of the reinfusion of 
cells subsets are designated as T N (naive), T CM (central memory), T EM (effector memory) and T Ef (effectors). Two dot-plots showing the CCR7/CD45RA phenotype of unfractionated CD8 + T cells from the same donor after a 5-day expansion with either stimuli are included for comparison. Triplicate analysis of purified populations was performed in sorting experiments of two donors.
T cells manipulated ex vivo cannot be drawn only from the function of those cells in vitro, and depends on a number of other factors. Aging of T cells as a result of ex vivo expansion is of critical importance for their replicative potential after adoptive transfer. Experiments to determine the effect of different protocols of expansion and transduction on the telomere dynamics and telomerase activity of T cells are underway in the laboratory. Another important issue to consider is the migratory properties of the cells reinfused, and their capability to maintain long-term immune survillance and mount recall Gene Therapy responses in vivo. CD8
+ T EM cells migrate to sites of inflammation , but they have lost the markers (CCR7, CD62L) that make it possible for them to recirculate between peripheral blood and secondary lymphoid organs such as lymph nodes, where recall responses occur. Nevertheless, this does not imply that CD8
+ T EM cells would not provide long-term immune responses, and we and others have shown that expression of CCR7 can be up-regulated by CD8
+ T EM cells in some circumstances, a process that depends on the stimulus and the cytokine environment. [23] [24] [25] 39 Further analysis of these rel-evant aspects is not possible from the design of our in vitro study.
We have studied the effect of polyclonal expansion with PHA and iCD3/iCD28 on the functional outcome of GM T-lymphocytes, and subsequently explored the underlying mechanisms. This study clearly demonstrates a functional disadvantage for PHA-based protocols of transduction of human T-lymphocytes, and identifies expansion protocols based on CD3/CD28 stimulation that maintain the ability of the target cells to respond in vitro to either allogeneic stimulation or viral antigens. Moreover, we have uncovered mechanisms that explain, at least in part, the reasons for this functional difference, and offer an explanation for the impaired function of PHA-expanded GM T cells reported in vivo in animal models and clinical trials. Overall, this information may help in the design and selection of protocols of retroviral transduction that preserve the function of GM T cells and potentially improve the benefit of their adoptive transfer into patients.
Materials and methods
Cell cultures: polyclonal expansion, mixed lymphocyte reaction (MLR), dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs)
Healthy donor PBMCs were isolated by centrifugation on a density gradient (Lymphoprep, Axis-Shield PoS AS, Oslo, Norway) following the manufacturer's instructions. PBMCs from each donor were expanded in parallel with either phytohemagglutinin (PHA; Murex Biotech, Dartford, UK) or plastic-bound anti-CD3 (clone OKT3, Ortho Biotech, Bucks, UK) plus anti-CD28 (clone CD28.2, BDPharmingen, Oxford, UK) in 24-well tissue culture plates (Falcon, Becton Dickinson Labware, Le Pont-de-Claix, France) in complete RPMI-1640 medium (supplemented with 10% (vol/vol) heat-inactivated fetal calf serum and 250 IU/ml penicillin/streptomycin) in the presence of 50 IU/ml human IL-2 (R&D Systems, Abingdon, UK). In MLR experiments, pre-expanded cells were washed twice and subsequently stimulated weekly at a 1:1 ratio with 35 Gy-irradiated allogeneic PBMCs. DCs were established from purified monocytes (anti-CD14 antibodies plus magnetic bead-selection; Miltenyi Biotech, Surrey, UK) cultured for 6 days in complete RPMI-1640 medium supplemented on days 0, 2 and 4 with 800 IU/ml GM-CSF and 500 IU/ml IL-4 (R&D Systems). Immature DCs were subsequently matured with 10 ng/ml TNF␣ (R&D Systems) and 15 g/mL PolyIC (Sigma-Aldrich, Poole, UK) for 2 additional days. The mature phenotype of DCs was confirmed by flow cytometry with a panel of monoclonal antibodies anti-CD14, -CD80, -CD83, -CD86, -HLA-DR, -CD40, -CD11c, and -CD54 (data not shown; BDPharmingen). Antigen-specific CTLs were generated from pre-expanded and fresh PBMCs stimulated with autologous mature peptide-pulsed DCs (50 g/ml for 2 h at 37°C; DC/responder ratio 1:10) in 1% ABS Ex-Vivo medium with 10 ng/ml IL7 (day 0; R&D Systems) and 20 IU/ml IL2 (starting on day 7), and harvested for analysis on day 12. The immunodominant HLA-A2-restricted NLVPMVATV peptide from the pp65 protein of CMV (CMVpp65 NLV ) 40 and HLA-B8-restricted FLRGRAYGL peptide from the latent cycle protein EBNA3A of EBV (EBV-EBNA3A FLR ) 41 were selected for this analysis. All cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 .
Detection of allo-specific T cells: proliferation assay
Allo-responsive proliferation of pre-expanded (5 days) PBMCs was analyzed by a standard assay of 3 H-thymidine incorporation in the last 18 h of 5-day MLRs (1 Ci/well; Amersham, Buckinghamshire, UK). Similar cultures without allogeneic stimulators were used as controls for the allo-specificity of proliferation.
Detection of allo-specific T cells:
51 Cr release assay CTLs generated in MLRs were harvested after three weekly rounds of allo-stimulation on day 20 and their cytolytic activity determined in standard 5-h 51 Cr release assays. Target cells included autologous and allogeneic (stimulator third party) PHA blasts. The percentage of specific lysis was calculated as 100% × (experimental release Ϫ spontaneous release)/(maximum release Ϫ spontaneous release). Spontaneous release was consistently below 15% of maximum release.
Tetrameric HLA class I/peptide complexes
The HLA-A2/CMVpp65 NLV and HLA-B8/EBV-EBNA3A FLR tetramers were produced as described previously. 42 Prokaryotic expression pET-3d vectors (Novagen, Nottingham, UK) encoding for the extracellular portion of HLA-A2 or -B8, each tagged to a carboxy terminal BirA enzyme recognition sequence and ␤2 microglobulin were separately transformed into Escherichia coli. Protein expression was induced with 1 mM isopropyl ␤-D-thio-galactopyranoside (Sigma-Aldrich) and chains were extracted from inclusion bodies, solubilized in 8 M urea and then refolded with the indicated peptides in denaturing conditions. Refolded complexes were purified by FPLC on a Superdex 75 column (Pharmacia Biotech, Buckinghamshire, UK) and biotinylated with BirA enzyme (Avidity, Denver, CO, USA). Monomeric biotinylated complexes were further purified by gel filtration, and then tetramerized by addition of phycoerythrin-labeled streptavidin (Sigma-Aldrich) at a 4:1 molar ratio.
Cell sorting and flow cytometric analysis of tetramers, intracellular staining, surface markers, cell cycle and apoptosis
Tetramer staining was performed on viral peptide-generated CTLs for 30 min at 37°C (1:100 tetramer dilution) as described before. 43 After tetramer staining, in some experiments, antigen-specific CTL-IFN␥ secretion was induced with specific peptide (10 M) and 3 g/ml anti-CD28 antibody (37°C, 6 h, with 3 M monensin; Calbiochem, La Jolla, CA, USA). Intracellular staining with monoclonal antibodies against IFN␥, perforin and granzyme A (BD Pharmingen) and their isotype controls was performed after cell permeabilization with Cytofix/Cytoperm Kit (BD Pharmingen). The following purified, FITC-, PE-, PerCP-, TC-, or APC-labelled antihuman monoclonal antibodies were also used in different combinations: anti-CCR7 (2H4, IgM); anti-NGFR (C40-1457, IgG1); anti-CD45RA (HI100, IgG2a; MEM56, IgG2b); anti-CD3 (UCHT1, IgG1); anti-CD8 (RPA-T8, IgG1); anti-CD4 (RPA-T4, IgG1); anti-CD14 (M5E2, IgG2a); anti-CD80 (DAL-1, IgG1); anti-CD83 (HB15, IgG2b); anti-CD86 (FUN-1, IgG1) ; anti-HLA-DR (TU36, IgG2b); anti-CD40 (14G7, IgM); anti-CD11c (B-ly6, IgG1); anti-CD54 (HA58, IgG1); goat anti-mouse IgM and IgG1 (all from BD-Pharmingen or Caltag Laboratories, Burlingame, CA, USA). Cell cycle distribution was analyzed by propidium iodide staining (1 mg/ml, 1 h; SigmaAldrich) after 70% cold ethanol fixation and 1 mg/ml RNAse (Sigma-Aldrich) treatment. Apoptosis was detected in the cultures by annexin V staining according to the manufacturer's instructions (Annexin V Fluos Staining Kit; Roche Diagnostics, Indianapolis, IN, USA). For multiple-color acquisition, compensation of fluorescence was set up with single and double fluorochromestained cells. Data were acquired on a FACSCalibur and analyzed using CellQuest software (Becton Dickinson Systems). Cell sorting was performed on a FACS Vantage (Becton Dickinson Systems).
Retroviral vector and packaging cell line pCC1 (Professor Bignon, Centre Jean Perrin, France) is a recently designed retroviral plasmid that comprises a HSV-TK/Sh-ble fusion gene driven by an internal simian virus 40 early promoter and a multiple cloning site under the transcriptional control of the Moloney MLV 5' long terminal repeat, 44 in which a truncated nerve growth factor receptor (tNGFR) gene 6, 45 was subcloned using Pfu DNA polymerase (Promega, Madison, WI, USA) and a set of primers with flanking BamHI and EcoRI restriction site sequences (forward, 5'-GGATCCATGGG GGCAGGTGCCACC-3'; reverse, 5'-GAATTCTCACCT CTTGAAGGCTATGTAGGCCACAAG-3').
Sequence analysis was performed to confirm the fidelity of the pCC1/tNGFR construct. 293GPG cells (Dr Dranoff, DanaFarber Cancer Institute, Boston, MA, USA) were used to produce retroviral particles pseudotyped with the VSV-G glycoprotein in a tetracycline-regulated fashion. 46 We have previously described the conditions for production, collection, concentration and storage of retroviral particles with this system. 47 
Transduction of human primary T-lymphocytes
PBMCs from healthy donors were expanded with polyclonal stimulus for 72 h, as described above. On day 4 expanded cells were transfered to 24-well plates coated with 20 g/cm 2 of recombinant human CH-296 fibronectin fragment (Retronectin, Takara Biomedicals, Shiga, Japan). Cells were plated at 0.4 × 10 6 /well in 1 ml of complete medium supplemented with 50 IU/ml IL-2 and subjected to three rounds of infection with 250 l of concentrated VSV-G pseudotyped pCC1/tNGFR particles on days 4 and 5. After each 4-h period of infection, half of the medium was replaced with fresh complete medium with 50 IU/ml IL2. Forty-eight hours were allowed for expression of the transgene, and subsequent analysis of the transduced cells was performed on day 8.
